Following the launch of multi-stakeholder recommendations in 2017, HIV Outcomes is calling for good practice examples from across the WHO Europe region on the long-term health, well-being and chronic care of people living with HIV for publication in an online compendium.

Called ESTICOM (European Surveys and Trainings to Improve MSM Community Health) the partnership will deliver on three inter-linked projects over three years from August 2016 to August 2019.

Given globalization and other social phenomena, controlling the spread of infectious diseases has become an imperative public health priority.

Merck announces week 96 data from pivotal Phase 3 drive-forward study of its investigational HIV therapy doravirine.

The mosaic Ad26/Ad26 plus gp140 HIV-1 vaccine induced comparable and robust immune responses in humans and rhesus monkeys, and it provided significant protection against repetitive heterologous SHIV challenges in rhesus monkeys. This vaccine concept is currently being evaluated in a phase 2b clinical efficacy study ...

The differential effects of commonly prescribed combined antiretroviral therapy (cART) regimens on AIDS-defining neurological conditions (neuroAIDS) remain unknown.

The study performed at the George Washington University presents a possible obstacle in finding a cure for HIV

Low-level HIV viral load, above the limit of detection, is an important warning signal for future treatment failure and World Health Organization guidelines on spotting treatment failure need to be revised to encourage greater vigilance and swifter action by healthcare providers in lower- and middle-income ...

The efficacy of antiretroviral therapy is significantly compromised by medication non-adherence. Long-acting enteral systems that can ease the burden of daily adherence have not yet been developed. Here we describe an oral dosage form composed of distinct drug–polymer matrices which achieved week-long systemic drug levels ...

Prevalence of silent cerebral small-vessel disease (SCSVD) – an important precursor to more serious neurocognitive conditions – is significantly higher among middle-aged HIV-positive patients compared to controls in the general population, according to French research published in Clinical Infectious Diseases.

Preliminary work in monkeys suggests stem cells can be engineered to help combat the virus

The type of vaccine administered and the activation of the body's own immune cells influence the vaccine protection.

People with HIV taking antiretroviral treatment who had undetectable viral load did not suffer any loss of cognitive function or brain volume during a two-year period when compared with their HIV-negative peers, but did have lower cognitive function and brain volume at the start of ...

Researchers caution against using antibodies to prevent transmission

Reducing the size of the HIV reservoir is viewed as an essential step in achieving a cure for HIV infection

Elicitation of a Key Precursor for Broadly Neutralizing Antibody for the HIV CD4 Binding Site

A study published in The Lancet HIV today showed that while the rate of newly reported HIV cases in Europe remained steady in younger people between 2004 and 2015, it increased by 2% each year overall in older people. With around 30 000 newly diagnosed ...

A three-pronged man-made antibody, created by French drugmaker Sanofi and U.S. scientists, could offer a new way to treat or prevent HIV, following successful tests in monkeys. Plans are under way to try the so-called trispecific antibody in initial human trials before the end of 2018, ...